A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway

Diagnosis and Treatment of Depression Clinical Trial

Official title:

Clinical Psychopharmacology Division Institute of Mental Health, Peking University

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03148509
• Other study ID #: Z171100000117016
• Status: Not yet recruiting
• Phase: Phase 4
• First received: May 8, 2017
• Last updated: May 10, 2017
• Start date: June 1, 2017
• Est. completion date: December 30, 2019

Study information

• Verified date: May 2017
• Source: Peking University
• Contact: Ji-Tao Li, MD
• Phone: 010-62723742
• Email: ljt_102124[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will recruit depressed patients unresponsive to selective serotonin reuptake inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls. The subjects need to complete the brain positron emission tomography/magnetic resonance examination, stress assessment, genetic testing, clinical evaluation and neuropsychological tests. Using the data, this study aimed to identify the abnormalities of reward circuit of depression and its differences with other diseases, and its abnormalities in first-degree relatives of depression. The depressed patients who were ineffective in treatment with selective serotonin reuptake inhibitor antidepressants were then given combined medication with dopamine receptor-mediated drugs, including dopamine transporter inhibitor - bupropion, D2 receptor antagonist - risperidone, or D2 receptor partial agonist - aripiprazole, to examine the regulation of dopamine pathway and its relationship with the therapeutic effect. Through the above work, we will provide new evidence for integrating the biological evidence of dopamine reward pathway into the clinical practice of depression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: December 30, 2019
• Est. primary completion date: December 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years to 55 Years

Eligibility

Inclusion Criteria:

• patients unresponsive to SSRI antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls

Exclusion Criteria:

• Major physical illness; other DSM-IV axis I mental illness; personality disorder, mental retardation; drug and/or alcohol dependence; pregnant or lactating women; MRI examination contraindications.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Diagnosis and Treatment of Depression

Intervention

Drug:
• risperidone
DA receptor-mediated drugs
• aripiprazole
DA receptor-mediated drugs
• bupropion
DA receptor-mediated drugs

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Rating Scale for Depression		8 weeks